Amneal Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Amneal Pharmaceuticals은 연평균 9.5%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 13.1%의 비율로 수입이 증가했습니다. 매출은 연평균 8.8%의 비율로 증가했습니다.

주요 정보

9.5%

수익 성장률

24.9%

EPS 성장률

Pharmaceuticals 산업 성장	7.3%
매출 성장률	8.8%
자기자본 수익률	n/a
순이익	-6.9%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Amneal Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:2DT 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	2,680	-184	457	183
30 Jun 24	2,598	-175	451	163
31 Mar 24	2,495	-169	440	165
31 Dec 23	2,394	-84	430	164
30 Sep 23	2,386	10	423	160
30 Jun 23	2,312	-2	410	169
31 Mar 23	2,272	-135	403	182
31 Dec 22	2,212	-130	400	196
30 Sep 22	2,139	-132	395	206
30 Jun 22	2,122	-134	386	204
31 Mar 22	2,098	2	373	206
31 Dec 21	2,094	11	366	202
30 Sep 21	2,067	14	353	203
30 Jun 21	2,058	9	345	199
31 Mar 21	1,987	-17	339	192
31 Dec 20	1,993	91	327	180
30 Sep 20	1,880	62	316	175
30 Jun 20	1,739	-194	297	168
31 Mar 20	1,679	-199	283	171
31 Dec 19	1,626	-362	290	188
30 Sep 19	1,727	-339	287	197
30 Jun 19	1,825	-67	298	202
31 Mar 19	1,834	-69	287	204
31 Dec 18	1,663	-21	228	194
30 Sep 18	1,459	155	184	180
30 Jun 18	1,237	149	136	179
31 Mar 18	1,083	168	106	176
31 Dec 17	1,034	168	109	171
30 Sep 17	1,039	54	113	171
31 Dec 16	1,018	207	119	179
31 Dec 15	866	169	110	137
31 Dec 14	786	177	85	107

양질의 수익: 2DT 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 2DT 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 2DT 은(는) 수익성이 없지만 지난 5년 동안 연간 9.5% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 2DT 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 2DT 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 28.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 2DT 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Amneal Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Recent updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold €236k worth of stock

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors

Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors

Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates

Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Amneal Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Amneal Pharmaceuticals, Inc. Reports Asset Impairment Charges for the Three Months Ended December 31, 2021